Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Oncogenic competence during development – When, Where and Why?

Project description

Understanding oncogenesis in paediatric cancer

The origins and drivers of developmental tumours continue to be major questions in paediatric oncology. Deadly childhood malignant rhabdoid tumours (MRTs) arise almost exclusively in the first two years of life, caused by inactivation of the SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) of the chromatin remodelling complex. The EU-funded ONCO-COMP project seeks to understand cell-autonomous and non-autonomous determinants of oncogenesis in case of SMARCB1 loss. The researchers will employ state-of-the-art genomics, transcriptomics, epigenetics, cell and imaging technologies, combined with integrative computational analyses, to conduct studies into transgenic mice, induced pluripotent stem cells, and patient-derived xenografts of MRTs. The goal is to develop an approach for the targeted treatments in MRT patients.

Objective

Childhood cancers are believed to be rooted in aberrant development, a notion supported by their (i) generally low mutational burden, (ii) high prevalence of single (often epigenetic) driver events and (iii) occurrence during confined developmental periods. Yet, the exact origins of developmental tumours remain one of the principal enigmas of pediatric oncology.

A prime example are malignant rhabdoid tumours (MRTs): they are astoundingly genomically simple but extremely deadly childhood cancers that arise almost exclusively in the first two years of life, and are driven by biallelic inactivation of the SWI/SNF chromatin remodelling complex subunit SMARCB1 (>95% of cases).

We still do not know what determines oncogenic competence upon SMARCB1 loss. In particular we wonder: (1) What are the cell(s)-of-origin of rhabdoid tumours and what is their normal differentiation potential? (2) What is the molecular framework that facilitates oncogenic transformation upon SMARCB1 loss? (3) What is the contribution of the niche (local and systemic) to the acquisition of oncogenic competence? And, considering the epigenetic nature of the oncogenic event, (4) is the oncogenic MRT state reversible, and how?

To answer these questions, we will combine state-of-the-art lineage-barcoded single-cell genomics, spatial transcriptomics, single-cell resolution wholemount imaging, CRISPR/Cas9 and epigenomic approaches, as well as integrative computational analyses, using transgenic mouse, induced pluripotent stem cell and patient-derived xenograft rhabdoid tumour models.

This project will provide fundamental insights into the cell autonomous and non-autonomous determinants of oncogenic competence upon SMARCB1 loss. Based on our findings we hope to unlock targeted treatments for MRT patients. Importantly, the conceptual and experimental framework we establish will open up new investigative opportunities for a multitude of developmental cancers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

FUNDACIO PRIVADA PER A LA RECERCA I LA DOCENCIA SANT JOAN DE DEU
Net EU contribution
€ 387 086,10
Address
SANTA ROSA 39-4
08950 Esplugues De Llobregat
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 387 086,10

Beneficiaries (2)